Research Article
Prognostic Factors for Clinical Response in Systemic Lupus Erythematosus Patients Treated by Allogeneic Mesenchymal Stem Cells
Table 2
Patient’s characteristics divided by CR.
| Variables | CR () | Without CR () | value |
| Age/years, median (range) | 38 (23-54) | 30 (20-54) | 0.03 | SLE duration/months, median (range) | 53.5 (13-232) | 78 (2-264) | 0.33 | Female | 15 (93.75%) | 46 (86.79%) | 0.67 | Prior SLE medication history | | | | Prednisone daily dose (mg) | | | | ≤20 | 5 (31.25%) | 23 (43.4%) | 0.39 | >20 | 11 (68.75%) | 30 (56.6%) | | CYC use | 6 (37.5%) | 41 (77.4%) | 0.003 | MMF use | 4 (25.0%) | 15 (28.3%) | 0.80 | HCQ use | 3 (18.8%) | 28 (52.8%) | 0.02 | LEF use | 1 (6.3%) | 13 (24.5%) | 0.11 | Clinical and biological symptoms | | | | Fever | 5 (31.3%) | 20 (37.7%) | 0.64 | Rash | 12 (75.0%) | 32 (60.4%) | 0.38 | Photosensitivity | 10 (62.5%) | 23 (43.4%) | 0.18 | Oral ulcers | 4 (25.0%) | 8 (15.1%) | 0.45 | Arthralgia/arthritis | 6 (37.5%) | 43 (81.1%) | 0.001 | Serositis | 1 (6.3%) | 16 (30.2%) | 0.09 | Vasculitis | 5 (31.3%) | 9 (17.0%) | 0.21 | Alopecia | 5 (31.3%) | 14 (26.4%) | 0.70 | Renal disorder | 14 (87.5%) | 50 (94.3%) | 0.33 | Active lupus nephritis | 13 (81.3%) | 50 (94.3%) | 0.10 | lupus nephritis® | | | | Stage III | 0 (0%) | 2 (20%) | 0.63 | Stage IV | 1 (100%) | 5 (50%) | | Stage V | 0 (0%) | 3 (30%) | | Neurologic disorder | 3 (18.8%) | 2 (3.8%) | 0.08 | Cardiorespiratory disorder | 2 (12.5%) | 17 (32.1%) | 0.20 | Hematological disorder | 7 (43.8%) | 25 (47.2%) | 0.81 | Immunologic disorder | 8 (50.0%) | 32 (60.4%) | 0.46 | Antinuclear antibodies | 11 (68.8%) | 43 (81.1%) | 0.29 | Anti-dsDNA | 6 (37.5%) | 21 (39.6%) | 0.88 | Anti-Sm | 4 (25.0%) | 17 (32.1%) | 0.76 | Anti-SSA | 6 (37.5%) | 11 (20.8%) | 0.17 | Anti-SSB | 0 (0%) | 6 (11.3%) | 0.32 | Low complement | 7 (43.8%) | 23 (43.4%) | 0.98 | CYC induction | | | | CYC induction | 7 (43.8%) | 35 (66.0%) | 0.11 | <1.2 g | 0 (0%) | 3 (8.6%) | 0.42 | ≥1.2 g | 7 (100%) | 32 (91.4%) | | Allo-MSC transplantation | | | | UC-MSCs | 10 (62.5%) | 41 (77.4%) | 0.33 | Second MSCs | 4 (25.0%) | 20 (37.7%) | 0.35 | SLEDAI median (range) | | | | Baseline | 13 (9-34) | 13 (8-27) | 0.72 | M1 | 6 (4-20) | 10 (4-18) | 0.01 | M3 | 6 (0-16) | 8 (4-14) | 0.04 | M6 | 4 (0-8) | 7 (3-18) | <0.001 | M12 | 2 (0-8) | 6 (4-18) | <0.001 |
|
|
CR: clinical remission; SLE: systemic lupus erythematosus; Anti-dsDNA: anti-double-stranded DNA antibody; Allo-MSCs: allogenic mesenchymal stem cells; BM: bone marrow-derived; UC: umbilical cord-derived; SLEDAI: Systemic Lupus Erythematosus Disease Activity Index; CYC: cyclophosphamide; MMF: mycophenolate mofetil; HCQ: hydroxychloroquine; LEF: leflunomide; M: follow-up months. Fisher test. ®Only for the patients with available kidney biopsy. |